Treventis
Treventis Corporation is a privately held biotechnology company focused on discovery and preclinical development of small-molecule therapeutics and diagnostics that target protein misfolding. The company uses a proprietary computational platform to model common conformational morphologies of intrinsically disordered and misfolded proteins (using homology modeling and molecular mechanics/dynamics) to enable virtual screening and structure-based hit-to-lead optimization. Treventis pursues programs across neurodegeneration (Alzheimer’s disease, ALS, Parkinson’s disease, tauopathies) and oncology (mutant p53) and works with industry partners and government funders to advance preclinical development and diagnostics.
Industries
Nr. of Employees
small (1-50)
Patents
Methods of treating amyloid disease using analogs of 1-(4-nitrophenyl) piperazine
US-8420640-B2
View Details
Methods of treating amyloid disease using analogs of 1-(4-nitrophenyl) piperazine
US-8420640-B2
View DetailsProducts
Tau and Aβ oligomer inhibitor programs
Preclinical discovery and optimization of small-molecule inhibitors intended to prevent or reduce tau and amyloid-β oligomerization; activities include computational modeling, biophysical characterization, cellular screening, medicinal chemistry, and in vivo target engagement studies.
Broad-spectrum TDP oligomer inhibitor
Discovery program to identify small molecules that inhibit misfolding and oligomerization of TAR DNA-binding protein (TDP) isoforms, aimed at arresting aggregate growth in ALS and TDP-mediated frontotemporal dementia.
p53 oligomer inhibitor
Program focused on discovery of small molecules that inhibit aggregation and oligomerization of mutant p53, with preliminary cell-based data showing selective growth inhibition of mutant-p53 cells and limited toxicity in wild-type cells.
Broad spectrum TDP oligomer inhibitor
A therapeutic program aiming to develop small molecules that inhibit the misfolding of TAR DNA-binding protein (TDP) isoforms to halt disease progression in Amyotrophic Lateral Sclerosis (ALS) and frontotemporal dementia (FTD).
CCM Technology
A proprietary, patented system known as common conformational morphology used to digitally screen, identify, and optimize classes of potent, drug-like compounds for anti-misfolding drug discovery.
Dual Aβ/tau oligomer inhibitor
Lead program concerning the design of small molecule anti-oligomerization agents for Alzheimer's and tauopathies using in silico Common Conformational Morphology (CCM) models of protein misfolding.
Tau and Aβ oligomer inhibitor programs
Preclinical discovery and optimization of small-molecule inhibitors intended to prevent or reduce tau and amyloid-β oligomerization; activities include computational modeling, biophysical characterization, cellular screening, medicinal chemistry, and in vivo target engagement studies.
Broad-spectrum TDP oligomer inhibitor
Discovery program to identify small molecules that inhibit misfolding and oligomerization of TAR DNA-binding protein (TDP) isoforms, aimed at arresting aggregate growth in ALS and TDP-mediated frontotemporal dementia.
p53 oligomer inhibitor
Program focused on discovery of small molecules that inhibit aggregation and oligomerization of mutant p53, with preliminary cell-based data showing selective growth inhibition of mutant-p53 cells and limited toxicity in wild-type cells.
Broad spectrum TDP oligomer inhibitor
A therapeutic program aiming to develop small molecules that inhibit the misfolding of TAR DNA-binding protein (TDP) isoforms to halt disease progression in Amyotrophic Lateral Sclerosis (ALS) and frontotemporal dementia (FTD).
CCM Technology
A proprietary, patented system known as common conformational morphology used to digitally screen, identify, and optimize classes of potent, drug-like compounds for anti-misfolding drug discovery.
Dual Aβ/tau oligomer inhibitor
Lead program concerning the design of small molecule anti-oligomerization agents for Alzheimer's and tauopathies using in silico Common Conformational Morphology (CCM) models of protein misfolding.
Expertise Areas
- Protein misfolding drug discovery
- Structure-based small-molecule design for intrinsically disordered proteins
- Medicinal chemistry and compound library generation
- Preclinical assay and model development for oligomerization
Key Technologies
- Computational conformational modeling of misfolded proteins
- Homology modeling
- Molecular mechanics / molecular dynamics simulations
- Virtual screening and structure-based drug design
News & Updates
Entered an option, collaboration and license agreement with a pharmaceutical company for further research and development of small molecules targeting tau in Alzheimer’s disease.
Received funding of $2,977,166 from the U.S. Department of Defense Congressionally Directed Medical Research Programs to support preclinical development of a small-molecule misfolding drug for frontotemporal dementia.
Awarded a U.S. Department of Defense grant of $489,738 to support exploration of anti-mutant-p53 targeting small molecules.
Established laboratory residency at a life-science incubator to support research activities.
Multiple company scientists presented and attended the Alzheimer Association International Conference, including a presentation on optimization of a murine CNS PK/PD model using systemic LPS administration and other biomarker and preclinical research presentations.
Company founder and head of diagnostics was elected a Fellow of the Canadian Academy of Health Sciences in recognition of leadership and scientific contributions, including work on radiotracer design for brain imaging and related laboratory activities.
Entered an option, collaboration and license agreement with a pharmaceutical company for further research and development of small molecules targeting tau in Alzheimer’s disease.
Received funding of $2,977,166 from the U.S. Department of Defense Congressionally Directed Medical Research Programs to support preclinical development of a small-molecule misfolding drug for frontotemporal dementia.
Awarded a U.S. Department of Defense grant of $489,738 to support exploration of anti-mutant-p53 targeting small molecules.
Established laboratory residency at a life-science incubator to support research activities.
Multiple company scientists presented and attended the Alzheimer Association International Conference, including a presentation on optimization of a murine CNS PK/PD model using systemic LPS administration and other biomarker and preclinical research presentations.
Company founder and head of diagnostics was elected a Fellow of the Canadian Academy of Health Sciences in recognition of leadership and scientific contributions, including work on radiotracer design for brain imaging and related laboratory activities.